Retail Offer

Summary by AI BETAClose X

CRISM Therapeutics Corporation is undertaking a retail offer to raise up to £100,000 by issuing new ordinary shares at 9 pence per share, with admission expected on December 16, 2025. This offer, alongside a separate placing, aims to fund the company's MHRA-approved Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients. The retail offer is exclusively for eligible investors in the United Kingdom and is conditional on the completion of the placing.

Disclaimer*

UK 100

Latest directors dealings